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Internal R&D, External R&D, and Firm Innovation 
Evidence from the Pharmaceutical Industry 
by Ning Wang 
Abstract 
The principal purpose of this dissertation is to develop a better understanding of 
the impact of internal and external research and development (R&D) strategies of 
firms on their innovative output. More specifically, three research questions have 
been empirically examined in the dissertation. First, what is the lag structure of the 
relationship between firm patenting and internal R&D? Second, under what condi-
tions is there complementarity or substitutability between internal and external 
R&D strategies in shaping a firm’s innovative output? Third, what is the impact of 
the structure of interfirm R&D alliance network on a focal firm’s innovative out-
put? 
The first study aims to revisit the classic research question regarding the lag 
structure of the patentsR&D relationship through an examination of the impact 
of internal R&D on firm patenting in the context of the global pharmaceutical 
industry. The empirical analysis in the study, using both a multiplicative distributed 
lag model and a dynamic linear feedback model, differs from previous work that 
examines the patentsR&D relationship in three aspects. First, the estimation 
results exhibit direct evidence on lagged R&D effects, with the first lag (t  1) of 
R&D being significant in all distributed lag specifications. Second, a U-shaped lag 
structure of the patentsR&D relationship is found in most estimations of the 
multiplicative distributed lag model, which suggests a potential long-run effect of 
internal R&D investments on firm patenting. Finally, the results from the dynamic 
linear feedback model coincide with those from the multiplicative distributed lag 
model, indicating not only lag effects from more recent R&D but, in support of 
the main hypothesis, also an overall long-run effect of internal R&D investments 
in the distant past on the knowledge production or innovation process of incum-
bent pharmaceutical firms. 
In contrast with the various strands of extant empirical research that are in-
conclusive about the complementarity or substitutability between different innova-
tion mechanisms, such as internal and external R&D, the second study of this 
dissertation suggests that, instead of a clear-cut answer to the question whether 
internal and external R&D are complementary or substitutive innovation activities, 
there appears to be a contingent relationship between internal and external R&D 
strategies in shaping a firm’s innovative output. The results from this study indicate 
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that the level of in-house R&D investments, characterized by decreasing marginal 
returns, is a contingency variable that critically influences the association between 
internal and external R&D strategies. More specifically, internal R&D and external 
R&D, through either R&D alliances or R&D acquisitions, are complementary 
innovation activities at higher levels of in-house R&D investments, whereas at 
lower levels of in-house R&D efforts, internal and external R&D turn out to be 
substitutive strategic options. 
The third study examines the impact of two aspects of interfirm alliance net-
work structure—structural holes and indirect ties—on a focal firm’s innovative 
output. A contingency approach is used by considering the various dimensions of a 
focal firm’s innovative output—new technology and new products—so as to iden-
tify their divergent requirements on the focal firm’s network structure of interfirm 
R&D alliances. The research setting for this study is the global pharmaceutical 
industry and the analytic focus is on incumbent pharmaceutical firms as the focal 
actors in the industry network. The results from the empirical analyses indicate that: 
(1) with regard to the relative efficacy of network closure vs. structural holes, an 
R&D alliance network rich in structural holes is more advantageous for incumbent 
pharmaceutical firms’ creation of new technology, whereas a dense, interconnected 
network turns out to be more beneficial for their development of new products; (2) 
concerning the dual role of indirect ties, incumbent pharmaceutical firms with 
more indirect ties in an R&D alliance network are actually associated with reduced 
innovative output in terms of new products, while no significant effect is found in 
the case of new technology. 
 
